Taking stock: where does Europe stand in the elimination of hepatitis B and C?
In 2016, a regional action plan for Europe that aims to contribute to the implementation of the global viral hepatitis elimination strategy was developed by the WHO Regional Office for Europe. In an article published today in Eurosurveillance, the authors take a closer look how Europe is doing according to the ten indicators and targets outlined in this plan. In short: Europe still has some way to go if it wants to eliminate viral hepatitis by 2030.
The United States Advisory Committee on Immunization Practices votes for near universal recommendation for seasonal influenza vaccinationArchived
The United States Advisory Committee on Immunization Practices (ACIP), which advises the Centers for Disease Control and Prevention (CDC) on vaccine issues, voted to approve a new recommendation on February 24 to offer seasonal influenza vaccination to the whole population aged 6 months and older.
Knowledge, attitudes and practices of business travelers regarding influenza and the use of antiviral medicationArchived
This descriptive study evaluated knowledge, attitudes and practices of Swiss business travelers with regards to influenza and the use of anti-viral medication.
Global Review of recent Antiviral Resistance dataArchived
Each year in February WHO convenes a meeting with advisers from the WHO Influenza Collaborating Centres and Essential Reference laboratories in order to achieve consensus and advise WHO on the optimal formulation of seasonal influenza vaccines for the next influenza season.
The use of Interferon-γ release assays for Tuberculosis Screening in International TravelersArchived
IGRAs are increasingly being considered for the diagnosis of LTBI, as a replacement to the TST, including travel medicine. As with the TST, many uncertainties remain with regard to the efficacy of the IGRAs. It is therefore essential to secure an accurate understanding of these assays‘ known efficacy, so that they be optimally used and only in context with proven effect.
Obesity and 2009 pandemic influenza A(H1N1) – its role and implications as an important risk factor for the development of severe influenza diseaseArchived
2 papers are reviewed: A Novel Risk Factor for a Novel Virus: Obesity and 2009 Pandemic Influenza A (H1N1) and Morbid Obesity as a Risk Factor for Hospitalization and Death Due to 2009 Pandemic Influenza A(H1N1) Disease.
Using Geographic Information Systems and Decision Support Systems for the Prediction, Prevention, and Control of Vector-Borne DiseasesArchived
Emerging and resurging vector-borne diseases cause significant morbidity and mortality, especially in the developing world. We focus on how advances in mapping, Geographic Information System, and Decision Support System technologies, and progress in spatial and space time modeling, can be harnessed to prevent and control these diseases.
Virological Risk Assessment of Pandemic Potential - EFSA Call for proposalsArchived
The European Food Standard Agency has recently published a call for proposals for a methodological framework for potentially pandemic influenza strains.
Poor pregnancy outcomes associated with maternal infection with the A(H1N1) 2009 virus during the pandemic – findings from a European cohort studyArchived
This large national cohort study followed-up pregnant women admitted to hospital and found to have laboratory-confirmed influenza A(H1N1) 2009 infection during the autumn-winter wave of the 2009 pandemic. The main objective was determining any adverse pregnancy outcomes attributable to the infection.